Opinion

Video

Patient Education Driving BTK Inhibitor Treatment Adherence

The criticality of patient education in BTKi use and its impact on treatment adherence is discussed.

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.

The group discusses considerations for educating and empowering patients receiving Bruton tyrosine kinase inhibitor (BTKi) therapy. As BTKis are given continuously long term, Dr Jacobs conceptualizes treatment as a marathon for patients. He emphasizes being upfront about common adverse effects and setting the expectation that doses can be reduced to mitigate toxicities without losing efficacy. This encourages patients to promptly communicate issues rather than try to push through them.

The experts recommend a patient-centered, shared decision-making approach involving the full care team, including pharmacy and nursing, to provide context and resources to help patients work through any adverse effects. Monitoring abandonment rates is also important to ensure patients from all backgrounds can remain on these long-term therapies. Effective patient education and support systems are crucial to facilitate optimal adherence throughout BTKi treatment.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo